Occurrence of hyperprogressive disease following administration of immune checkpoint inhibitors in lung squamous cell carcinoma: A case report
- Authors:
- Published online on: August 8, 2022 https://doi.org/10.3892/etm.2022.11554
- Article Number: 617
-
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Immunotherapy through blocking programmed cell death 1, programmed death‑ligand 1 and cytotoxic T lymphocyte antigen 4 is developing rapidly and has gained increasing attention as a treatment for malignant tumors. However, some patients experience varying degrees of immune‑related side effects after undergoing immunotherapy, with hyperprogressive disease (HPD) occurring in severe cases which increases the risk of mortality. The present study discussed the risk factors for HPD following immunotherapy in a case of lung squamous cell carcinoma, after treatment with a combination of anti‑angiogenic drugs and biological cytotoxic drugs, the mass was found to have become smaller than before, along with follow‑up treatment options, to provide a reference for clinical treatment decisions.
